AnaptysBio, Inc.
NASDAQ:ANABBiotechnology
-$1.07 today
- Market cap
- $1.40B
- Beta
- 0.41
- P/E (TTM)
- -59.7
- EPS (TTM)
- -$0.93
Volume 0.57M
Average 0.76M
ANAB Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
AnaptysBio, Inc.NASDAQ: ANAB
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $25.56M fell 8.0% year over year, behind the +107.7% change in trailing-twelve-month revenue. Sequentially, it fell 76.4% from the prior quarter. Over 3 fiscal years it compounded at +183.6% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of $151.74M (-35.3%) for the fiscal year ending Dec 2026, a slowdown from the +157.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $25.56M-76.4% QoQ
- Last fiscal yearDec 2025
- $234.6M+157.0% YoY
- LTMMar 2026
- $232.39M+107.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -8.0% | +0.0% | +8.0 pp |
| 1 year | +157.0% | -35.3% | -192.3 pp |
| 3-year CAGR | +183.6% | +9.1% | -174.5 pp |
| 5-year CAGR | +11.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 234.6M USD
- Year-over-year change
- +157.0%
- 4-year CAGR
- +38.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 234.6M | +157.0% |
| FY2024 | 2024-12-31 | 91.28M | +432.0% |
| FY2023 | 2023-12-31 | 17.16M | +66.8% |
| FY2022 | 2022-12-31 | 10.29M | -83.7% |
| FY2021 | 2021-12-31 | 63.18M | — |
Revenue vs competitors
How ANAB compares with its peers on the latest reported figures
- ANAB's LTM Mar 2026 revenue of $232.39M is the highest of the 10 companies compared; the peer median is $1.9M.
- Its year-over-year change of +107.7% is the highest of 5, against a peer median of -56.9%.
- Over three fiscal years its annual growth of +183.6% compares with a peer median of -20.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $232.39M | +107.7% | +183.6% | |
| LTM Jun 2026 | $104.97M | -36.1% | -8.6% | |
| LTM Mar 2026 | $53.74M | — | +100.7% | |
| LTM Mar 2026 | $8.37M | -52.9% | -35.9% | |
| LTM Sep 2026 | $7.1M | — | — | |
| LTM Jun 2026 | $1.9M | -60.8% | -31.8% | |
| FY2025 | $64K | -99.8% | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $0 | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
| Peer median (excluding ANAB) | $1.9M | -56.9% | -20.2% | |
Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.18M | 10.29M | 17.16M | 91.28M | 234.6M |
| Cost of Revenue | 98.5M | 88.8M | 132.28M | 163.84M | 2.42M |
| Gross Profit | (35.32M) | (78.51M) | (115.13M) | (72.56M) | 232.18M |
| Gross Margin | -55.9% | -763.2% | -671.0% | -79.5% | 99.0% |
| Research & Development | 98.5M | 88.8M | 139.62M | 163.84M | 135.97M |
| Selling, General & Admin | 21.49M | 36.64M | 41.95M | 42.39M | 50.74M |
| Operating Expenses | 21.49M | 36.64M | 49.29M | 42.39M | 184.28M |
| Depreciation & Amortization | 2.09M | 2.34M | 652K | 2.4M | 2.42M |
| EBITDA | (55.71M) | (105.26M) | (156.42M) | (92.74M) | 69.25M |
| EBITDA Margin | -88.2% | -1023.2% | -911.7% | -101.6% | 29.5% |
| Operating Income | (56.81M) | (115.15M) | (164.41M) | (114.95M) | 47.9M |
| Operating Margin | -89.9% | -1119.4% | -958.3% | -125.9% | 20.4% |
| Interest Income | 431K | 7.55M | 18.87M | 19.79M | 13.5M |
| Interest Expense | 1.45M | 21.11M | 18.08M | 50.09M | 79.89M |
| Other Income / Expenses | (982K) | (13.55M) | 788K | (30.28M) | (60.96M) |
| Income Before Tax | (57.8M) | (128.7M) | (163.62M) | (145.23M) | (13.07M) |
| Pre-Tax Margin | -91.5% | -1251.1% | -953.7% | -159.1% | -5.6% |
| Income Tax Expense | 0 | 24K | (4K) | 3K | 164K |
| Net Income | (57.8M) | (128.72M) | (163.62M) | (145.23M) | (13.23M) |
| Net Margin | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% |
| EPS (Basic) | (2.11) | (4.57) | (6.08) | (5.12) | (0.46) |
| EPS (Diluted) | (2.11) | (4.57) | (6.08) | (5.12) | (0.46) |
| Weighted Avg Shares | 27.43M | 28.17M | 26.92M | 28.38M | 27.79M |
| Weighted Avg Shares (Diluted) | 27.43M | 28.17M | 26.92M | 28.38M | 31.34M |
AnaptysBio, Inc.
NASDAQ:ANAB
Intrinsic Alpha fair value
Locked
Current Price
$47.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.